Diagnostic Accuracy and Predictive Factors of Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma: A Systematic Review
Open Access
- 30 September 2026
- journal article
- review article
- Published by SAGE Publications in Plastic Surgery
Abstract
Introduction: Sentinel lymph node biopsy (SLNB) is increasingly used to stage cutaneous squamous cell carcinoma (cSCC), particularly in high-risk cases, though its diagnostic accuracy remains debated. This systematic review aims to evaluate SLNB detection rates, diagnostic accuracy, complications and predictors of positivity in patients with non-mucosal cSCC. Methods: Following PRISMA guidelines, Medline, Embase, Scopus and Cochrane Library were searched to January 2025. Studies reporting SLNB outcomes in histologically confirmed cSCC were included. Pediatric and mucosal/anogenital cases were excluded. Data on demographics, tumour characteristics, SLNB outcomes and complications were extracted. Comparisons between SLNB-positive, negative and false-negative groups were performed ( p < 0.05). Results: Forty-four studies (3043 patients, 3050 lesions) were included. Among 2956 patients undergoing SLNB, nodes were identified in 96.9%, with positivity in 10.9%. False negatives occurred in 1.7% of the cases (rate 13.2%). SLNB-positive patients had larger tumours (4.24 vs 2.88 cm, p < 0.0001) and deeper invasion (9.81 vs 4.75 mm, p = 0.0007), higher rates of perineural invasion ( p = 0.0436), poor differentiation ( p = 0.009) and more T2 disease ( p = 0.04). No significant differences were found for sex ( p = 0.5), immunosuppression ( p = 0.068) or tumour location ( p = 0.1), though immunosuppression was more prevalent in SLNB-positive cases. Recurrence (24.3% vs 4.2%) and disease-specific mortality (18.2% vs 3.7%) were higher in SLNB-positive patients ( p < 0.0002). Complication rates were low (3.2%). Conclusion: SLNB demonstrates high detection but notable false negative rates in cSCC. Positive SLNB correlates with aggressive tumour features and worse outcomes. SLNB may assist staging in high-risk patients but should be used selectively, with close surveillance in SLNB-negative cases.Keywords
This publication has 25 references indexed in Scilit:
- Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and ScotlandEuropean Journal of Cancer, 2023
- Sentinel lymph node biopsy for early squamous cell carcinoma of the lip and oral cavity: Real‐world experience in BrazilHead & Neck, 2022
- Sentinel lymph node biopsy for head and neck cutaneous squamous cell carcinoma using the Brigham and Women’s staging system: a cost analysisArchives of Dermatological Research, 2022
- Introduction to PRISMA 2020 and implications for research synthesis methodologistsResearch Synthesis Methods, 2021
- Guidelines of care for the management of cutaneous squamous cell carcinomaJournal of the American Academy of Dermatology, 2018
- Cutaneous squamous cell carcinomaJournal of the American Academy of Dermatology, 2018
- Clinical and Incidental Perineural Invasion of Cutaneous Squamous Cell CarcinomaJAMA Dermatology, 2017
- Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific DeathJAMA Dermatology, 2016
- Sentinel lymph node biopsy in early breast cancer surgery – Working with the risks of vital blue dye to reap the benefitsEuropean Journal of Surgical Oncology, 2011
- Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: Case series and review of the literatureEuropean Journal of Surgical Oncology, 2007